Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2019 / N 2

Низкомолекулярные гепарины во флебологической практике: в фокусе парнапарин
В.Ю. Богачев, Б.В. Болдин, С.В. Родионов

Список литературы

1. The vein book. Bergan JJ, Bunke-Paquette N, editors. 2nd ed. NY: Oxford University Press; 2014. 568 p.
2. Cronenwett JL, Johnston KW. Rutherford’s vascular surgery. 8th ed. 2-vol. set. Philadelphia, PA: Saunders/Elsevier; 2014. 2784 p.
3. Blossom DB, Kallen AJ, Patel PR, Alexis Elward, Robinson L, Gao G, Langer R, Perkins KM, Jaeger JL, Kurkjian KM, Jones M, Schillie SF, Ketterer D, Venkataraman G, Kishimoto TK, Kei T, Shriver Z, McMahon AW, Austen KF, Kozlowski S, Srinivasan A, Turabelidze G, Gould CV, Arduino MJ, Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. The New England Journal of Medicine 2008 Dec;359:2674-84.
4. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. The New England Journal of Medicine 2008 Jun;358(23):2457-67.
5. Gray E, Mulloy B. Biosimilar low molecular heparin products. Journal of Thrombosis and Haemostasis 2009 Jul;7(7):1218-21.
6. Gainor C, Vanscoy GJ, Niccolai CS, Rihn TL. Pharmacologic and liability considerations of therapeutic interchange with low-molecular-weight heparins. Hospital Pharmacy 2003 Jul;38(7):652-8.
7. Явелов И.С. Препараты низкомолекулярного гепарина: основные свойства и возможности создания аналогов. Клиническая фармакология и терапия 2010;19(1):56-63.
8. Camporese G, Bernardi E, Noventa F. Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vascular Health and Risk Management 2009;5:819-31.
9. Морозов К.М., Колбин А.С., Галанкин Т.Л. Сетевой мета-анализ эффективности применения парнапарина для профилактики венозных тромбоэмболических осложнений при хирургических вмешательствах. Тромбоз, гемостаз и реология 2018;73(1):31-9.
10. Imberti D, Baldini E, Giorgi M, Pierfranceschi MG, Nicolini A, Cartelli C, De Paoli M, Boni M, Filippucci E, Cariani S, Bottani G. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery 2014 Feb;24(2):284-91.
11. Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and Expert Panel report. Chest 2016 Feb;149(2):315-52.
12. McKeage K, Keating GM. Parnaparin a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs 2008;68(1):105-22.
13. Стойко Ю.М., Кириенко А.И., Илюхин Е.А., Лобастов К.В., Чаббаров Р.Г., Париков М.А., Хорев Н.Г., Золотухин И.А., Андрияшкин В.В., Карпенко А.А., Фокин А.А., Сушков С.А., Сапелкин С.В., Сучков И.А., Крылов А.Ю., Игнатьев И.М. Диагностика и лечение тромбофлебита поверхностных вен конечностей. Рекомендации Ассоциации флебологов России. Флебология 2019;13(2):78-97.
14. Superficial thrombophlebitis treated by Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archive of Internal Medicine 2003 Jul;163(14):1657-63.
15. Cosmi B, Fillippinni M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Palareti G; STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparine) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis 2012 Jun;10(6):1026-35.
16. Kalodiki E, Stvrtinova V, Allegra C, Andreozzi GM, Antignani PL, Avram R, Brkljacic B, Cadariou F, Dzsinich C, Fareed J, Gaspar L, Geroulakos G, Jawien A, Kozak M, Lattimer CR, Minar E, Partsch H, Passariello F, Patel M, Pécsvárady Z, Poredos P, Roztocil K, Scuderi A, Sparovec M, Szostek M, Skorski M; the International Union of Angiology (IUA), the International Union of Phlebology (IUP), the Central European Vascular Forum (CEVF) and Vasculab. Superficial vein thrombosis: a consensus statement. International Angiology 2012;31:203-16.
17. Богачев В.Ю., Болдин Б.В., Дженина О.В., Лобанов В.Н. Тромбофлебит (тромбоз поверхностных вен): современные стандарты диагностики и лечения. Стационарзамещающие технологии: Амбулаторная хирургия 2016;3-4:16-23.
18. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, Giannoukas AD, Lugli M, Maleti O, Myers K, Nelzén O, Partsch H, Perrin M. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. International Angiology 2018 Jun;37(3):181-254.

References

1. The vein book. Bergan JJ, Bunke-Paquette N, editors. 2nd ed. NY: Oxford University Press; 2014. 568 p.
2. Cronenwett JL, Johnston KW. Rutherford’s vascular surgery. 8th ed. 2-vol. set. Philadelphia, PA: Saunders/Elsevier; 2014. 2784 p.
3. Blossom DB, Kallen AJ, Patel PR, Alexis Elward, Robinson L, Gao G, Langer R, Perkins KM, Jaeger JL, Kurkjian KM, Jones M, Schillie SF, Ketterer D, Venkataraman G, Kishimoto TK, Kei T, Shriver Z, McMahon AW, Austen KF, Kozlowski S, Srinivasan A, Turabelidze G, Gould CV, Arduino MJ, Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. The New England Journal of Medicine 2008 Dec;359:2674-84.
4. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. The New England Journal of Medicine 2008 Jun;358(23):2457-67.
5. Gray E, Mulloy B. Biosimilar low molecular heparin products. Journal of Thrombosis and Haemostasis 2009 Jul;7(7):1218-21.
6. Gainor C, Vanscoy GJ, Niccolai CS, Rihn TL. Pharmacologic and liability considerations of therapeutic interchange with low-molecular-weight heparins. Hospital Pharmacy 2003 Jul;38(7):652-8.
7. Yavelov IS. Low molecular weight heparins: basic properties and possibilities of creating analogues. Clinical Pharmacology and Therapy 2010;19(1):56-63 (In Russian).
8. Camporese G, Bernardi E, Noventa F. Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vascular Health and Risk Management 2009;5:819-31.
9. Morozov KM, Kolbin AS, Galankin TL. Network meta-analysis of parnaparin efficacy in prevention of venous thromboembolic complications in surgery. Tromboz, Gemostaz i Reologia 2018;73(1):31-9 (In Russian).
10. Imberti D, Baldini E, Giorgi M, Pierfranceschi MG, Nicolini A, Cartelli C, De Paoli M, Boni M, Filippucci E, Cariani S, Bottani G. Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obesity Surgery 2014 Feb;24(2):284-91.
11. Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and Expert Panel report. Chest 2016 Feb;149(2):315-52.
12. McKeage K, Keating GM. Parnaparin a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs 2008;68(1):105-22.
13. Stoyko YuM, Kiriyenko AI, Ilyukhin EA, Lobastov KV, Chabbarov RG, Parikov MA, Khorev NG, Zolotukhin IA, Andriyashkin VV, Karpenko AA, Fokin AA, Sushkov SA, Sapelkin SV, Suchkov IA, Krylov AYu, Ignatyev IM. Diagnosis and treatment of superficial vein thrombophlebitis. Guidelines of the Russian Phlebological Association. Phlebologiya. Journal of Venous Disorders 2019;13(2):78-97 (In Russian).
14. Superficial thrombophlebitis treated by Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archive of Internal Medicine 2003 Jul;163(14):1657-63.
15. Cosmi B, Fillippinni M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Palareti G; STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparine) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis 2012 Jun;10(6):1026-35.
16. Kalodiki E, Stvrtinova V, Allegra C, Andreozzi GM, Antignani PL, Avram R, Brkljacic B, Cadariou F, Dzsinich C, Fareed J, Gaspar L, Geroulakos G, Jawien A, Kozak M, Lattimer CR, Minar E, Partsch H, Passariello F, Patel M, Pécsvárady Z, Poredos P, Roztocil K, Scuderi A, Sparovec M, Szostek M, Skorski M; the International Union of Angiology (IUA), the International Union of Phlebology (IUP), the Central European Vascular Forum (CEVF) and Vasculab. Superficial vein thrombosis: a consensus statement. International Angiology 2012;31:203-16.
17. Bogachev VYu, Boldin BV, Jenina OV, Lobanov VN. Thrombophlebitis (superficial vein thrombosis): modern standards of diagnosis and treatment. Ambulatory Surgery: Hospital-replacing Technologies 2016;3-4:16-23 (In Russian).
18. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, Giannoukas AD, Lugli M, Maleti O, Myers K, Nelzén O, Partsch H, Perrin M. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. International Angiology 2018 Jun;37(3):181-254.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]